Fig. 2

Increase in AD-related phenotypes by APOE ε4 expression from the amyloid-seeding stage. a Representative immunofluorescence images of Aβ42-positive iNs of the PSEN1 mutation line at day 25. To express APOE ε4 in AD patient iNs, doxycycline was added on day 7 or 14. Scale bar, 20 µm. b Relative intensity of Aβ42-positive cells in APOE ε3- or APOE ε4-expressing AD patient iNs at different amyloid stages. Data represent mean ± SEM. ANOVA-test, *P < 0.05, **P < 0.01; n = 6 per sample. c Ratio of Aβ42 to Aβ40 concentration in APOE ε3- or APOE ε4-expressing AD patient iNs. Data represent mean ± SEM. ANOVA-test, *P < 0.05, **P < 0.01; n = 3 per sample. d Relative intensity of amyloid oligomers in APOE ε3- or APOE ε4-expressing AD patient iNs at different amyloid stages. Data represent mean ± SEM. ANOVA-test, *P < 0.05, **P < 0.01; n = 5 per sample. e Representative image of western blot analysis showing the level of Aβ (6E10) oligomers in APOE ε4-expressing AD patient iNs harboring PSEN2 mutation at different amyloid stages. f Relative intensity of amyloid oligomers in APOE ε4-expressing AD patient iNs harboring PSEN2 mutation. Data represent mean ± SEM. ANOVA-test, *P < 0.05, **P < 0.01; n = 4 per sample. g Representative immunofluorescence images of hyperphosphorylated tau in APOE ε4-expressing AD patient iNs harboring PSEN1 mutation on day 25. Scale bar, 20 µm. h Measurement of phospho-tau-positive inclusions compared to the total area at different amyloid stages. Data represent mean ± SEM. ANOVA-test, *P < 0.05, **P < 0.01; n = 5 per sample. i Representative images of thioflavin T staining in APOE ε4-expressing AD patient iNs harboring PSEN1 mutation at different amyloid stages. White arrows indicate thioflavin T-positive area. Scale bar, 20 µm. j Quantification of thioflavin T-positive area in APOE ε4-expressing AD patient iNs. Data represent mean ± SEM. ANOVA-test, *P < 0.05, **P < 0.01; n = 5 per sample. + APOE4 (day 7): AD patient iNs expressing APOE ε4 from day 7; + APOE4 (day 14): AD patient iNs expressing APOE ε4 from day 14; -APOE4: AD patient iNs with no APOE ε4 expression